# Surgery Partners, Inc. (SGRY) Stock Analysis: Exploring a 14.84% Upside Potential with Strong Buy Ratings

- Link: https://www.directorstalkinterviews.com/surgery-partners-inc-sgry-stock-analysis-exploring-a-14-84-upside-potential-with-strong-buy-ratings/4121257156
- Published: 2026-07-21T10:21:58+01:00
- Author: Madison Wilson

Surgery Partners, Inc. (SGRY), a prominent player in the U.S. healthcare sector,
stands at an intriguing crossroads for investors. With a market capitalization of
$2.1 billion, this Brentwood, Tennessee-based company specializes in operating a
network of surgical facilities, focusing on non-emergency procedures across various
disciplines such as orthopedics, ophthalmology, gastroenterology, and more. The 
company’s strategic emphasis on ambulatory surgery centers and surgical hospitals
positions it well within the medical care facilities industry.

Currently trading at $16.03, Surgery Partners’ stock has experienced a relatively
stable performance with a 52-week range between $11.49 and $23.84. The stock’s recent
price change was a minimal 0.04 (0.00%), indicating a period of consolidation. However,
what makes the stock particularly interesting is its potential upside of 14.84%,
as indicated by the average target price of $18.41 from analysts.

The valuation metrics for Surgery Partners present a mixed picture. While the trailing
P/E ratio and PEG ratio are not available, the forward P/E ratio stands at 24.50,
suggesting that the stock is priced for future growth. The absence of a P/E ratio
and other traditional valuation metrics like Price/Book and EV/EBITDA might be a
point of concern for some investors, but it can also indicate the potential for 
unrecognized value.

Performance metrics reveal a revenue growth of 4.50%, which, although modest, demonstrates
the company’s ability to maintain steady expansion in a competitive market. However,
the negative earnings per share (EPS) of -0.59 and the absence of net income suggest
profitability challenges. Despite these hurdles, the company has managed a positive
return on equity of 2.75% and boasts a robust free cash flow of approximately $199
million, underscoring its operational efficiency and potential to fund growth initiatives.

From a dividend perspective, Surgery Partners does not currently offer a yield, 
with a payout ratio of 0.00%. This may appeal to investors focused on capital appreciation
rather than income generation.

Analyst sentiment towards Surgery Partners is predominantly positive, with 9 buy
ratings and 3 hold ratings, and no sell ratings. This favorable outlook reflects
confidence in the company’s strategic direction and market positioning. The target
price range spans from $14.00 to $24.00, with the current price offering a potential
upside that adds to its investment appeal.

Technical indicators provide additional insights into the stock’s trajectory. The
50-day moving average of $14.85 and the 200-day moving average of $15.68 suggest
that the stock is trading above its recent trend lines, a positive technical signal.
The Relative Strength Index (RSI) of 59.34 indicates that the stock is neither overbought
nor oversold, positioning it neutrally in terms of momentum. The MACD at 0.36, with
a signal line of 0.50, further supports a cautious optimism about the stock’s short-
term performance.

As Surgery Partners continues to navigate the complexities of the healthcare landscape,
its focus on specialized, non-emergency surgical services could provide a sustained
competitive edge. For investors seeking exposure to the healthcare sector with a
growth-oriented company, Surgery Partners, Inc. offers a compelling proposition 
with a significant potential upside and a strong buy consensus from analysts.

Share on:
